Korean J Urol.  2014 Mar;55(3):196-200. 10.4111/kju.2014.55.3.196.

Comparative Efficacy of Tamsulosin Versus Tamsulosin With Tadalafil in Combination With Prednisolone for the Medical Expulsive Therapy of Lower Ureteric Stones: A Randomized Trial

• Kumar S
• Jayant K
• Agrawal S
• Singh SK

• KMID: 1988424
• DOI: http://doi.org/10.4111/kju.2014.55.3.196

Abstract

PURPOSE
To compare the safety and efficacy of tamsulosin and tamsulosin with the phosphodiesterase-5 inhibitor tadalafil in combination with prednisolone as medical expulsive therapies for lower ureteric stones.
MATERIALS AND METHODS
Between July 2011 and December 2012, 62 adult patients presenting with distal ureteric stones sized 5 to 10 mm were randomized equally to treatment with tamsulosin (group A) or tamsulosin with tadalafil (group B). Therapy was given for a maximum of 6 weeks. In addition, patients in groups A and B were given 5-mg prednisolone once daily (maximum 1 week). The stone expulsion rate, time to stone expulsion, analgesic use, number of hospital visits for pain, follow-up and endoscopic treatment, and adverse effects of the drugs were noted. Statistical analyses were done by using Student t-test and chi-square test.
RESULTS
There was a higher expulsion rate (83.9% in group B and 74.2% in group A) and a lower time to expulsion in both treatment groups than in historical controls used in earlier studies. However, these results were not statistically significant (p=0.349, p=0.074, respectively). Statistically significant differences were noted in hospitalization for colic and analgesic requirement, which were less in group B than in group A. There were no serious adverse events. Another important finding was improvement in erectile function in group B.
CONCLUSIONS
Medical expulsive therapy for distal ureteric stones using tamsulosin and tadalafil with prednisolone is safe and efficacious. Also, the prescription of tadalafil in cases of erectile dysfunction with the development of lower ureteric stones may provide additional advantages.

Keyword

Prednisolone; Tadalafil; Tamsulosin; Urinary calculi

MeSH Terms

Adult
Colic
Cyclic Nucleotide Phosphodiesterases, Type 5
Erectile Dysfunction
Follow-Up Studies
Hospitalization
Humans
Male
Prednisolone*
Prescriptions
Ureter*
Urinary Calculi
Cyclic Nucleotide Phosphodiesterases, Type 5
Prednisolone

Reference

1. Hollingsworth JM, Rogers MA, Kaufman SR, Bradford TJ, Saint S, Wei JT, et al. Medical therapy to facilitate urinary stone passage: a meta-analysis. Lancet. 2006; 368:1171–1179.

2. Ueno A, Kawamura T, Ogawa A, Takayasu H. Relation of spontaneous passage of ureteral calculi to size. Urology. 1977; 10:544–546.

3. Porpiglia F, Vaccino D, Billia M, Renard J, Cracco C, Ghignone G, et al. Corticosteroids and tamsulosin in the medical expulsive therapy for symptomatic distal ureter stones: single drug or association? Eur Urol. 2006; 50:339–344.

4. Singh SK, Agarwal MM, Sharma S. Medical therapy for calculus disease. BJU Int. 2011; 107:356–368.

5. Wang CJ, Huang SW, Chang CH. Efficacy of an alpha1 blocker in expulsive therapy of lower ureteral stones. J Endourol. 2008; 22:41–46.

6. Gratzke C, Uckert S, Reich O, Schlenker B, Tilki D, Seitz M, et al. PDE5 inhibitors. A new option in the treatment of ureteral colic. Urologe A. 2007; 46:1219–1223.

7. Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol. 2012; 61:917–925.

8. Coll DM, Varanelli MJ, Smith RC. Relationship of spontaneous passage of ureteral calculi to stone size and location as revealed by unenhanced helical CT. AJR Am J Roentgenol. 2002; 178:101–103.

9. Hubner WA, Irby P, Stoller ML. Natural history and current concepts for the treatment of small ureteral calculi. Eur Urol. 1993; 24:172–176.

10. Seitz C, Liatsikos E, Porpiglia F, Tiselius HG, Zwergel U. Medical therapy to facilitate the passage of stones: what is the evidence? Eur Urol. 2009; 56:455–471.

11. Hochreiter WW, Danuser H, Perrig M, Studer UE. Extracorporeal shock wave lithotripsy for distal ureteral calculi: what a powerful machine can achieve. J Urol. 2003; 169:878–880.

12. Segura JW, Preminger GM, Assimos DG, Dretler SP, Kahn RI, Lingeman JE, et al. Ureteral Stones Clinical Guidelines Panel summary report on the management of ureteral calculi. The American Urological Association. J Urol. 1997; 158:1915–1921.

13. Bensalah K, Pearle M, Lotan Y. Cost-effectiveness of medical expulsive therapy using alpha-blockers for the treatment of distal ureteral stones. Eur Urol. 2008; 53:411–418.

14. Wolf JS Jr. Treatment selection and outcomes: ureteral calculi. Urol Clin North Am. 2007; 34:421–430.

15. Sigala S, Dellabella M, Milanese G, Fornari S, Faccoli S, Palazzolo F, et al. Evidence for the presence of alpha1 adrenoceptor subtypes in the human ureter. Neurourol Urodyn. 2005; 24:142–148.

16. Kumar S, Kurdia KC, Ganesamoni R, Singh SK, Nanjappa B. Randomized controlled trial to compare the safety and efficacy of naftopidil and tamsulosin as medical expulsive therapy in combination with prednisolone for distal ureteral stones. Korean J Urol. 2013; 54:311–315.

17. Porpiglia F, Ghignone G, Fiori C, Fontana D, Scarpa RM. Nifedipine versus tamsulosin for the management of lower ureteral stones. J Urol. 2004; 172:568–571.

18. Parsons JK, Hergan LA, Sakamoto K, Lakin C. Efficacy of alpha-blockers for the treatment of ureteral stones. J Urol. 2007; 177:983–987.

19. Dellabella M, Milanese G, Muzzonigro G. Randomized trial of the efficacy of tamsulosin, nifedipine and phloroglucinol in medical expulsive therapy for distal ureteral calculi. J Urol. 2005; 174:167–172.

20. Kaplon DM, Sterrett S, Nakada SY. Medical management of acute urolithiasis in one American academic emergency room. BJU Int. 2010; 105:856–858.

21. Gratzke C, Uckert S, Kedia G, Reich O, Schlenker B, Seitz M, et al. In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach. Urol Res. 2007; 35:49–54.

22. Taher A, Schulz-Knappe P, Meyer M, Truss M, Forssmann WG, Stief CG, et al. Characterization of cyclic nucleotide phosphodiesterase isoenzymes in the human ureter and their functional role in vitro. World J Urol. 1994; 12:286–291.

23. Kuhn R, Uckert S, Stief CG, Truss MC, Lietz B, Bischoff E, et al. Relaxation of human ureteral smooth muscle in vitro by modulation of cyclic nucleotide-dependent pathways. Urol Res. 2000; 28:110–115.

24. Becker AJ, Stief CG, Meyer M, Truss MC, Forssmann WG, Jonas U. The effect of the specific phosphodiesterase-IV-inhibitor rolipram on the ureteral peristalsis of the rabbit in vitro and in vivo. J Urol. 1998; 160(3 Pt 1):920–925.

25. Lue TF, Broderich GA. Evaluation and nonsurgical management of erectile dysfunction and premature ejaculation. In : Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh urology. 4th ed. Philadelphia: Saunders/Elsevier;2007. p. 750–787.

26. Kloner RA, Jackson G, Emmick JT, Mitchell MI, Bedding A, Warner MR, et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol. 2004; 172(5 Pt 1):1935–1940.

27. Kloner RA. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation. 2004; 110:3149–3155.

28. Bechara A, Romano S, Casabe A, Haime S, Dedola P, Hernandez C, et al. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med. 2008; 5:2170–2178.

29. Kinnman E, Nygards EB, Hansson P. Peripheral alpha-adrenoreceptors are involved in the development of capsaicin induced ongoing and stimulus evoked pain in humans. Pain. 1997; 69:79–85.

30. Nayak S, Acharjya B. Deflazacort versus other glucocorticoids: a comparison. Indian J Dermatol. 2008; 53:167–170.